ABBV
AbbVie’s blood-cancer encore
AbbVie showed up at EHA 2026 with fresh Phase 3 data on its fixed-duration venetoclax-based combo for first-line chronic lymphocytic leukemia. Translation: the company is trying to remind everyone that VENCLEXTA/VENCLYXTO is still very much in the game, and apparently doing the long-haul endurance event too.
Why investors should care
This matters because long-term data is the biotech version of a sequel that doesn’t stink. If nine-year outcomes keep looking solid, it helps support the drug’s staying power in a crowded blood-cancer market and gives AbbVie more ammo to defend one of its key oncology assets.
The not-so-small print
- The data were presented at the European Hematology Association 2026 Congress in Stockholm, which runs from June 11th to June 14th.
- AbbVie described the readout as Phase 3 data from a fixed-duration venetoclax-based combination.
- The headline hook here is the nine-year treatment outcome, which is the kind of phrase that makes investors sit up and ask, “Okay, but does it still work after all that time?”
Big picture
For AbbVie, the goal is simple: keep showing that its cancer franchise isn’t just a one-hit wonder. In biotech, durability is the product, and this readout is AbbVie saying, yep, the story still has legs.